[{"bbox": [91, 99, 367, 130], "category": "Page-header", "text": "Q-Line Biotech Limited"}, {"bbox": [91, 170, 236, 198], "category": "Text", "text": "forth below:"}, {"bbox": [1110, 233, 1556, 265], "category": "Text", "text": "(Rs. in lakhs, except per share data)"}, {"bbox": [91, 262, 1346, 659], "category": "Table", "text": "<table><thead><tr><th>Audited<br>Information</th><th>For the year ended<br>March 31, 2025</th><th>For the year ended<br>March 31, 2024</th><th>For the year ended<br>March 31, 2023</th></tr></thead><tbody><tr><td>Equity Share Capital (₹)</td><td>1.00</td><td>1.00</td><td>1.00</td></tr><tr><td>Reserves & Surplus</td><td>(23.83)</td><td>11.71</td><td>(1.99)</td></tr><tr><td>Net worth</td><td>(22.83)</td><td>12.71</td><td>(0.99)</td></tr><tr><td>Total Revenue (including<br>other income)</td><td>165.48</td><td>68.45</td><td>0.15</td></tr><tr><td>Profit/(Loss) after tax</td><td>(35.54)</td><td>13.71</td><td>(1.99)</td></tr><tr><td>Basic and Diluted Earnings<br>per share<br>(face value of ₹ 10 each)</td><td>(355.36)</td><td>137.06</td><td>(19.98)</td></tr><tr><td>Net asset value per share (₹)</td><td>(228.28)</td><td>127.08</td><td>(9.98)</td></tr></tbody></table>"}, {"bbox": [99, 695, 518, 725], "category": "Section-header", "text": "### g. Accumulated profits or losses"}, {"bbox": [91, 757, 1556, 821], "category": "Text", "text": "Our Company acquired shares of QLIPL on March, 07, 2025, thereby making it a subsidiary company. As a result, the requirement to accumulate profits or losses of QLIPL does not arise."}, {"bbox": [91, 855, 404, 884], "category": "Section-header", "text": "* **Other Confirmations:**"}, {"bbox": [91, 919, 177, 949], "category": "Section-header", "text": "**Listing**"}, {"bbox": [91, 982, 1558, 1076], "category": "Text", "text": "The equity shares of our Subsidiary Company are not listed on any Stock Exchange. None of the securities of our Subsidiary company have been refused listing by any stock exchange in India or abroad or failed to meet the listing requirements of any stock exchange in India or abroad."}, {"bbox": [91, 1111, 292, 1139], "category": "Section-header", "text": "**Business interest**"}, {"bbox": [91, 1174, 1558, 1270], "category": "Text", "text": "Our Subsidiary does not have any business or other interest in our Company other than as stated in section titled \"Our Business\", and transactions disclosed in the section titled \"Restated Financial Statements -Related party disclosures\", on page 123, 179 and 227 respectively of this Draft Red Herring Prospectus."}, {"bbox": [91, 1304, 307, 1334], "category": "Section-header", "text": "**Common pursuits**"}, {"bbox": [91, 1367, 1558, 1431], "category": "Text", "text": "As on the date of this Draft Red Herring Prospectus, our Subsidiary Company is not involved in ventures which are in the same line of business as of our Company."}, {"bbox": [802, 2171, 848, 2200], "category": "Page-footer", "text": "319"}]